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Abstract: Post-traumatic stress disorder (PTSD) develops in a portion of individuals exposed to
extreme trauma. Glycosylation is a post-translational modification that affects protein functions and is
altered in various pathophysiological states and aging. There are still no validated biomarkers of PTSD.
The aim of this study was to evaluate the N-glycomic profile in 543 male Caucasian individuals (299
veterans with PTSD and 244 control subjects). The study included discovery (N = 233) and replication
(N = 310) cohort. Hydrophilic interaction HPLC and ultra-performance liquid chromatography were
used to separate and detect 39 plasma and 24 IgG N-glycan species, respectively. All results were
corrected for the effects of age and multiple testing. Significant results included only significantly
altered N-glycans in cases/controls in both cohorts, in the same direction. Results showed that six
plasma N-glycans (four increased and two decreased) were altered in PTSD vs. controls in both
cohorts, but IgG N-glycans were similar between groups. The severity of PTSD was not associated
with different plasma N-glycans. This is the first study detecting alterations in plasma N-glycans in
PTSD. These N-glycans are also associated with other neuropsychiatric disorders and inflammation,
suggesting possible shared glycosylation mechanisms.
Keywords: biomarkers; Caucasians; immunoglobulin G; male subjects; N-glycans; plasma;
PTSD; veterans
1. Introduction
Post-traumatic stress disorder (PTSD) is a trauma- and stressor-related disorder [1] that develops in
a portion of individuals who show distress and functional impairment after experiencing or witnessing
a traumatic event. PTSD symptom clusters include re-experiencing, avoidance, negative thoughts,
negative mood, and hyperarousal [1]. The prevalence of PTSD differs according to differences in
trauma exposure and trauma types worldwide and can be regionally specific. Combat and war-related
traumas are associated with 11–20% prevalence in United States combat veterans [2], whereas in
Croatian combat exposed veterans, the estimated prevalence of PTSD ranges from 14 to 40% [3]. PTSD
is associated with different somatic comorbidities such as metabolic syndrome, increased inflammatory
processes, pulmonary, cardiovascular and autoimmune diseases [4–7], and it is recognized as systemic
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disease [8]. Due to its complex etiology, the biological underpinning of PTSD is still not clear, validated
and clinically useful biomarkers have not been identified, and various potential suggested biomarkers
were not replicated [9].
N-glycans are complex carbohydrate chains linked by N-glycosidic bonds to various proteins
or lipids. Glycosylation is a post-translational modification that affects diverse protein functions
such as cell adhesion, signal transduction, receptor activation, molecular trafficking, and systemic
clearance [10]. N-glycans affect different cellular processes and biological functions [11]. Altered
glycosylation in plasma, serum, and cerebrospinal fluid (CSF) is found in cancer, autoimmune,
infectious and chronic inflammatory diseases [11,12] and aging [12–14]. N-glycans attached to IgG,
constituting 10–20% of plasma proteins, have been associated with the pathogenesis and progression
of different diseases, and biological age [12]. Beside these somatic disorders, changes in plasma,
serum and CSF glycosylation patterns were found in different neuropsychiatric diseases, such as
schizophrenia [15], major depressive disorder (MDD) [16], attention-deficit hyperactivity disorder
(ADHD) [17], dementia [14] and Alzheimer’s disease (AD) [18]. To date, only one study evaluated
9 N-glycan structures and accelerated aging in a small number of trauma exposed subjects [19].
An association between particular protein glycosylation in highly stressed groups, such as in professional
soldiers was detected in earlier study [20]. Although the authors did not use highly specific and robust
N-glycosylation profiling, they reported a significantly higher concentration of the highly-sialylated
glycoprotein stressin whose concentration was positively correlated with stress intensity [20].
PTSD is a severe disorder that significantly impairs normal functioning and quality of life of
affected persons and their families [9]. Therefore, better understanding of the biological basis of
PTSD is extremely important. The exact biological factors associated with vulnerability or resilience
to PTSD are still unknown, but vulnerability is presumably the result of the complex interplay
between environmental, biological, and genetic factors. Clinically useful and validated biomarkers
of PTSD, that will enable insight into the biological alterations in PTSD, are missing [9]. N-glycans
are usually considered as mediators between environmental stimuli and genetic background that are
highly responsible for crucial physiological processes and are strongly affected by age [14], sex [21],
and ethnicity [22]. Therefore, the aim of this study was to compare the N-glycosylation profile between
war veterans with PTSD and age-, sex-, and ethnicity- matched healthy control subjects. The goal of
the study was to identify validated and clinically useful biomarkers of PTSD. The hypothesis of this
study was that alterations in plasma/IgG N-glycome will be associated with PTSD and/or severity
of PTSD symptoms. We also predicted, based on the preliminary results of the accelerated aging in
PTSD [19] that veterans with PTSD will have higher values on the GlycoAge Test than control subjects,
indicating faster aging in PTSD.
2. Methods
2.1. Participants
The study design included two cohorts: discovery and replication, which together comprise 543
age-matched unrelated male Caucasian individuals of Croatian origin: 299 with combat-related PTSD
and 244 age-matched control subjects, not exposed to combat trauma. Discovery cohort was enrolled
in the period between autumn of 2015 and spring of 2016, whereas the samples for the replication
cohort were collected in the period between autumn of 2016 and the spring of 2017. Individuals had
current and chronic PTSD, diagnosed using the Structured Clinical Interview (SCID) based on DSM-5
criteria [1]. At the time of sampling, individuals with PTSD did not receive psychiatric medication for
at least 30 days. Control (N = 73) and subjects with PTSD (N = 160) in the discovery cohort (N = 233)
were sampled from October 2015 to January 2016, whereas control (N = 171) and subjects with PTSD
(N = 139) in the replication cohort (N = 310) were sampled from October 2016 to February 2017.
Individuals with PTSD were 39–77 years old, with exposure to warzone trauma during the Homeland
war in Croatia (1991–1995). The median age (25th; 75th percentile) of PTSD patients was 55 (50; 59) and
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56 (52; 53) in the discovery and replication cohort, respectively, whereas the median age (25th; 75th
percentile) of control subjects was 53 (48; 58) and 57 (49; 63) in the discovery and replication cohort,
respectively. The Clinician Administered PTSD Scale (CAPS) [23] was used to assess severity of PTSD.
According to the CAPS severity, individuals with PTSD were subdivided into those with moderate
(range: 66–95 CAPS scores) and severe (range: 96–136 CAPS scores) PTSD symptoms. There were no
individuals with mild PTSD symptoms (range: 46–65 CAPS scores). Median number of CAPS scores
(25th; 75th percentile) was 86 (78; 88) in the discovery cohort and 85 (78; 86) in the replication cohort.
The median BMI (25th; 75th percentile) of healthy control subjects was 27.4 (25.7; 30.0) and 29.0 (27.2;
31.2) in the discovery and replication cohort, respectively; whereas median BMI (25th; 75th percentile)
of individuals with PTSD was 27.7 (25.8; 30.3) and 28.1 (25.7; 30.5) in the discovery and replication
cohort, respectively.
Exclusion criteria were chronic drug abuse, alcohol dependence or pathophysiological changes
in the liver, MDD, schizophrenia, bipolar disorder, adult ADHD, AD, current or recent (previous
3 months) use of lipid lowering agents, antihypertensive, and antidiabetic medication. All participants
were additionally evaluated according to the International Classification of Diseases (ICD-10) to exclude
potential somatic disease such as fibrosis, sclerosis, cirrhosis and malignant liver disease (alcoholic liver
cirrhosis (K70.3), alcoholic liver fibrosis and sclerosis (K70.2), and hepatocellular carcinoma (C22.0))
that might affect N-glycan levels.
Healthy control subjects were evaluated with the same diagnostic instruments and followed the
same inclusion/exclusion criteria. The aims and procedures of the study were explained in detail to all
participants. Written informed consent was obtained from all subjects/patients. The authors assert that
all procedures contributing to this work comply with the ethical standards of the relevant national
and institutional committees on human experimentation and with the Helsinki Declaration of 1975,
as revised in 2008. All procedures involving human subjects/patients were approved by the Ethics
Committee of the University Psychiatric Hospital Vrapce, Zagreb, Croatia.
2.2. Blood Sampling
Blood samples were collected between 7:30 and 8:00 a.m., after overnight fasting, using BD
Vacutainer™ glass blood collection tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA)
with acid citrate dextrose (ACD). Immediately after blood sampling, platelet poor plasma was separated
by series of centrifugation and stored at −80 ◦C. Plasma samples, in both cohorts, were randomized
and blinded prior to N-glycan determination to avoid bias.
3. N-glycan Determination in Plasma
3.1. Glycan Release and Labelling in Plasma
Plasma N-glycans were determined as described previously [24]. Plasma samples (10 µL) were
mixed with 20 µL of 2% (w/v) SDS (Invitrogen, Camarillo, CA, USA) for 10 min at 65 ◦C in order
to achieve protein denaturation in the samples, followed by addition of 4% (v/v) Igepal CA630
(SigmaAldrich, St. Louis, MO, USA) to the mixture. N-glycans were released by digestion with 1.2 U
PNGase F (Promega, San Luis Obispo, CA, USA) overnight, at 37 ◦C. Following extraction, glycans
were fluorescently labeled with 2-aminobenzamide (2-AB) after 2 h incubation at 65 ◦C. To prepare
the labeling solution, 2-AB (19.2 mg/mL; SigmaAldrich, St. Louis, MO, USA) and 2-picoline borane
(44.8 mg/mL; SigmaAldrich) were dissolved in a mixture of dimethylsulfoxide (SigmaAldrich, St.
Louis, MO, USA) and glacial acetic acid (Merck, Darmstadtd, Germany) (70:30 v/v).
3.2. Hydrophilic Interaction High Performance Liquid Chromatography (HILIC)
Released glycans were subjected to HILIC, Acquity UPLC instrument (Waters, Milford, MA, USA),
on a Waters BEH Glycan chromatography column, 150 × 2.1 mm i.d., 1.7 µm BEH particles at 25 ◦C
with 100 mM ammonium formate adjusted to pH 4.4 (solvent A) and acetonitrile (solvent B). Samples
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were kept at 10 ◦C before the injection. The separation was achieved with a linear gradient of solvent A
(30–47%) at 0.56 mL/min flow rate, during 23 min long analysis. Runs were performed with fluorescence
detector set with excitation and emission wavelengths of 250 and 428 nm, respectively. The system
was calibrated using an external standard of hydrolyzed and 2-AB-labeled glucose oligomers from
which the retention times for the individual glycans were converted to glucose units. The obtained
chromatograms were all separated into 39 chromatographic areas (peaks) and automatic processing
method, with a traditional integration algorithm, was used to process the data. The amounts of glycan
present in each area were expressed as the percent of total integrated chromatogram and the peaks
were assigned as described by Saldova and colleagues [25].
4. N-glycan Determination in IgG
4.1. Glycan Release and Labelling in IgG
Plasma samples (50 µL) were diluted 10x with the binding buffer and applied to the Protein G
plate. The filtration of the samples was completed in approximately 5 min. The plate was washed five
times with 5 column volumes (CV) of binding buffer to remove unbound proteins. IgG was released
from the protein G monoliths using 5 CV of elution solvent (0.1 M formic acid, pH 2.5). Eluates
were collected in a 96 deep-well plate and neutralized to pH 7.0 with 1 M ammonium bicarbonate
to maintain the IgG stability. After each sample application, the monoliths were regenerated with
the following buffers: 10 CV of 10× PBS, followed by 10 CV of 0.1 M formic acid and 10 CV of 1×
PBS to re-equilibrate the monoliths. Each step of the chromatographic procedure was done under
vacuum (cca. 60 mmHg pressure reduction while applying the samples, 500 mmHg during elution and
washing steps). The purity of the isolated IgG was verified by SDS-PAGE with NuPAGE Novex 4–12%
Bis-Tris gels in an Xcell SureLock Mini-Cell (Invitrogen) according to the manufacturer. Precision Plus
Protein All Blue Standards (BioRad, Hercules, CA, USA) were used as the molecular weight markers.
The gels were run at 180 V for 45 min, stained with GelCode Blue (Thermo Fisher scientific, Waltham,
MA, USA) and visualized by a VersaDoc Imaging System (BioRad, Hercules, CA, USA).
4.2. Ultraperformance Liquid Chromatography (UPLC) Analysis of IgG Glycans
Fluorescently labelled N-glycans were separated by UPLC on a Waters Acquity UPLC instrument
consisting of a quaternary solvent manager, sample manager and a FLR fluorescence detector set with
excitation and emission wavelengths of 330 and 420 nm, respectively. The instrument was under
the control of Empower 2 software, build 2145 (Waters, Milford, MA, USA). Labeled N-glycans were
separated on a Waters BEH Glycan chromatography column, 100 × 2.1 mm i.d., 1.7 µm BEH particles,
with 100 mM ammonium formate (pH 4.4) and acetonitrile. The separation method was developed,
which uses a linear gradient of 75–62% acetonitrile at a flow rate of 0.4 mL/min in a 20 min analytical
run. Samples were maintained at 5 ◦C prior to injection, and the separation temperature was 60 ◦C.
The system used hydrolyzed and 2-AB labeled glucose oligomers as external standard, from which
the retention times for the individual glycans were converted to glucose units. Data processing was
performed using an automatic method with a traditional integration algorithm after which each
chromatogram was manually corrected to maintain the same intervals of integration for all the samples.
The obtained chromatograms were separated into 24 peaks representing percentage of total integrated
area as described previously [14].
5. Statistical Analysis
To remove experimental variation from measurements, normalization and batch correction were
performed on UPLC glycan data. Normalization of raw measurements within each sample is required
because intensities of UPLC signals can vary more than 100-fold due to experimental noise. Also,
laboratory conditions can vary during the experiment, so correction of batch effects is necessary [26].
To make measurements across samples comparable, normalization by total area is performed where
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peak area of each glycan structure was divided by total area of corresponding chromatogram. Prior
to batch correction, normalized glycan measurements were log transformed due to right-skewness
of their distributions and multiplicative nature of batch effects. Batch correction was performed
on log-transformed measurements using ComBat method [27], R package sva [28], where technical
source of variation (which sample was analyzed on which plate) was modeled as batch covariate.
To get measurements corrected for experimental noise, estimated batch effects were subtracted from
log-transformed measurements.
The results are expressed as medians and 25th (Q1) and 75th (Q3) percentiles and were evaluated
with R Statistics 3.5.1. Normality of the distribution was assessed with the Kolmogorov–Smirnov
test. As most of the glycan peaks were not normally distributed, non-parametric analyses were
used. The 39 plasma and 24 IgG N-glycans are shown as percentages of the total area under the
curve. Besides individual N-glycans in plasma and IgG, GlycoAge index was calculated for each
individual. GlycoAge index was determined as a logarithmic ratio of two N-glycan structures that
showed the highest changes in concentration depending on age: agalactosylated core-a-1,6-fucosylated
biantennary N-glycan (FA2), which concentration increases gradually with age and bigalactosylated
core-a-1,6-fucosylated biantennary N-glycan (FA2G2), which concentration decreases with aging
(log10(FA2/FA2G2)) [14]. Plasma and IgG samples from the PTSD and control group are shown
separately for the discovery and the replication study. Multiple linear regression was used to determine
the effect of age, BMI and smoking on levels of plasma and IgG N-glycan species. As the age is a
main predictor of N-glycosylation changes in human plasma [29] and IgG [30], correction for the
effect of age was performed by fitting the linear model of each glycan peak in dependence of age
and using the obtained residuals for further statistical analysis [19]. Differences in the distribution of
N-glycans and GlycoAge index values between veterans with PTSD and control subjects, and between
PTSD severity subgroups were evaluated using Mann-Whitney tests with corrected N-glycan values.
Correlations between N-glycans and severity of PTSD were analyzed with Spearman’s rank tests.
False discovery rate (Benjamini Hochberg) method was used to correct p values due to the multiple
testing. The corrected values at p < 0.05 were considered significant.
6. Results
Multiple linear regression analyses revealed that in our sample smoking and BMI were not
significantly associated with majority of N-glycans in plasma (p > 0.05) or IgG (p > 0.05). However,
as expected, there was a strong association of N-glycans with age, and therefore all glycan values were
corrected for age (Supplementary Tables S3 and S4). The analysis of the entire glycome included 39
N-glycans in plasma (Table 1, Supplementary Figure S1) and 24 IgG N-glycans (Table 2, Supplementary
Figure S2).
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Table 1. Distribution of total plasma N-glycans in healthy controls and patients with PTSD in discovery and replication cohort. Results are presented as age adjusted
percentage of total glycan peak area (median, 25th, and 75th percentile).
Plasma
N-glycan
Peak
Discovery Cohort (N = 233) Replication Cohort (N = 330)
Control (N = 73) PTSD (N = 160) Statistics Control (N = 171) PTSD (N = 139) Statistics
Median 25th 75th Median 25th 75th MW U p Median 25th 75th Median 25th 75th MW U p
GP1 4.615 3.885 5.514 4.161 3.392 5.103 4810.0 0.062 5.457 4.454 6.559 5.895 4.568 6.843 11094.0 0.524
GP2 1.994 1.740 2.267 1.970 1.726 2.261 5630.0 0.777 2.168 1.911 2.449 2.237 1.901 2.510 11476.0 0.719
GP3 0.084 0.071 0.101 0.089 0.068 0.109 5448.0 0.515 0.103 0.083 0.125 0.106 0.087 0.132 11490.0 0.719
GP4 3.759 3.232 4.411 3.234 2.867 3.711 3783.0 <0.001 3.770 3.178 4.426 3.666 3.183 4.308 11793.0 0.908
GP5 2.062 1.658 2.394 1.684 1.394 1.971 3475.0 <0.001 2.085 1.645 2.570 1.961 1.617 2.393 10989.0 0.484
GP6 1.212 1.048 1.387 1.157 1.025 1.341 5085.0 0.182 1.336 1.162 1.503 1.336 1.131 1.506 11633.0 0.810
GP7 1.023 0.960 1.124 0.979 0.902 1.144 5235.0 0.304 1.059 0.945 1.180 0.991 0.885 1.110 9285.0 0.014
GP8 1.046 0.993 1.134 1.088 0.974 1.189 5260.0 0.310 1.047 0.964 1.173 1.113 1.017 1.246 9453.0 0.016
GP9 0.098 0.087 0.112 0.099 0.083 0.113 5827.0 0.986 0.111 0.095 0.127 0.109 0.092 0.126 11156.0 0.545
GP10 3.345 2.983 4.145 2.809 2.313 3.501 3820.0 <0.001 3.157 2.529 3.822 3.064 2.511 3.573 11242.0 0.612
GP11 0.701 0.641 0.880 0.701 0.590 0.840 5516.0 0.603 0.820 0.710 0.939 0.757 0.654 0.894 9913.0 0.043
GP12 0.998 0.939 1.062 1.022 0.905 1.105 5414.0 0.481 1.005 0.927 1.089 0.972 0.885 1.070 10629.0 0.278
GP13 0.710 0.627 0.875 0.655 0.559 0.761 4210.0 0.002 0.801 0.683 0.943 0.775 0.626 0.933 11038.0 0.489
GP14 12.136 11.145 12.590 12.476 11.790 13.067 4261.0 0.003 11.478 10.904 12.237 11.823 11.177 12.529 9652.0 0.025
GP15 0.396 0.349 0.451 0.443 0.377 0.509 4278.0 0.003 0.518 0.448 0.582 0.474 0.427 0.546 9919.0 0.043
GP16 4.716 4.240 5.276 4.262 3.813 4.843 4080.0 0.001 4.807 4.236 5.467 4.594 4.028 5.060 9813.0 0.038
GP17 1.652 1.480 1.977 1.779 1.410 2.272 5254.0 0.310 2.063 1.763 2.404 1.844 1.598 2.224 9375.0 0.014
GP18 3.714 3.174 4.006 3.363 3.073 3.765 4873.0 0.082 3.158 2.865 3.495 3.144 2.900 3.619 11353.0 0.712
GP19 0.957 0.873 1.051 0.902 0.829 0.982 4627.0 0.023 0.974 0.869 1.030 0.902 0.828 0.991 8778.0 0.003
GP20 29.128 27.579 30.740 29.152 27.525 30.769 5657.0 0.802 26.692 24.870 27.838 26.487 24.682 28.160 11505.0 0.719
GP21 0.510 0.466 0.544 0.513 0.468 0.545 5391.0 0.463 0.616 0.560 0.664 0.612 0.557 0.662 11575.0 0.771
GP22 4.243 3.813 4.699 3.859 3.422 4.258 4089.0 0.001 4.001 3.607 4.529 3.936 3.459 4.572 10881.0 0.403
GP23 2.009 1.585 2.420 2.029 1.545 2.372 5687.0 0.833 2.281 1.930 2.751 2.163 1.805 2.632 10772.0 0.360
GP24 1.383 1.240 1.725 1.532 1.232 1.814 5061.0 0.171 1.432 1.130 1.693 1.442 1.191 1.739 11457.0 0.719
GP25 0.292 0.269 0.316 0.294 0.270 0.319 5717.0 0.839 0.274 0.252 0.299 0.279 0.247 0.305 11409.0 0.719
GP26 1.434 1.340 1.731 1.621 1.402 1.836 4590.0 0.020 1.534 1.322 1.720 1.499 1.275 1.683 10634.0 0.278
GP27 0.690 0.528 0.891 0.884 0.662 1.084 4160.0 0.002 0.946 0.734 1.117 1.075 0.853 1.263 9374.0 0.014
GP28 0.683 0.589 0.767 0.672 0.551 0.795 5831.0 0.986 0.636 0.520 0.736 0.604 0.508 0.739 11157.0 0.545
GP29 0.201 0.170 0.231 0.184 0.158 0.220 4975.0 0.127 0.181 0.154 0.201 0.172 0.155 0.203 11454.0 0.719
GP30 4.684 4.279 5.584 5.210 4.170 5.869 5029.0 0.156 4.826 3.944 5.490 4.602 3.892 5.347 10852.0 0.397
GP31 0.425 0.358 0.523 0.430 0.339 0.525 5703.0 0.838 0.433 0.350 0.531 0.395 0.320 0.478 9931.0 0.043
GP32 1.503 1.199 1.730 1.774 1.468 2.045 3733.0 <0.001 1.598 1.344 1.846 1.594 1.315 1.894 11696.0 0.848
GP33 2.807 2.083 3.490 3.523 2.781 4.361 3883.0 <0.001 3.504 2.766 4.213 4.049 3.165 4.728 9528.0 0.018
GP34 0.347 0.310 0.409 0.395 0.342 0.445 4210.0 0.002 0.385 0.340 0.454 0.384 0.347 0.434 11482.0 0.719
GP35 0.352 0.261 0.460 0.424 0.335 0.546 4287.0 0.003 0.417 0.346 0.518 0.454 0.369 0.566 10481.0 0.211
GP36 0.488 0.429 0.549 0.603 0.547 0.690 2393.0 <0.001 0.557 0.485 0.627 0.593 0.515 0.651 10436.0 0.200
GP37 0.412 0.349 0.473 0.465 0.371 0.568 4533.0 0.015 0.452 0.385 0.553 0.462 0.389 0.546 11712.0 0.848
GP38 0.890 0.737 1.013 1.067 0.936 1.258 3029.0 <0.001 1.038 0.923 1.222 1.098 0.985 1.234 10786.0 0.360
GP39 0.783 0.645 0.920 1.062 0.856 1.300 2931.0 <0.001 1.000 0.826 1.318 1.133 0.974 1.481 9822.0 0.038
GlycoAge 0.112 0.017 0.238 0.163 0.040 0.295 5126.0 0.208 0.219 0.128 0.384 0.256 0.145 0.394 11021.0 0.489
Results of the statistics are denoted as Mann Whitney U value (MW U) and false discovery rate (FDR) adjusted p value (p), where significant results are shown in bold. GP = glycan peak;
GlycoAge index = log 10(FA2/FA2G2); PTSD = post-traumatic stress disorder.
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Table 2. Distribution of N-glycan structures on IgG in healthy controls and patients with PTSD in discovery and replication cohort. Results are presented as age
adjusted percentage of total glycan peak area (median, 25th, and 75th percentile).
IgG
N-glycan
Peak
Discovery cohort (N = 233) Replication cohort (N = 330)
Control (N = 73) PTSD (N = 160) Statistics Control (N = 171) PTSD (N = 139) Statistics
Median 25th 75th Median 25th 75th MW U p Median 25th 75th Median 25th 75th MW U p
GP1 0.085 0.070 0.111 0.089 0.072 0.110 5668.0 0.889 0.097 0.080 0.114 0.100 0.081 0.124 11164.0 0.778
GP2 0.536 0.368 0.719 0.642 0.399 0.924 4887.0 0.170 0.739 0.515 1.001 0.710 0.493 1.111 11671.0 0.987
GP3 0.104 0.088 0.116 0.108 0.091 0.125 5009.0 0.288 0.123 0.111 0.141 0.125 0.110 0.140 11811.0 0.987
GP4 21.850 17.974 25.144 22.733 19.818 27.247 4905.0 0.218 24.042 21.203 28.427 25.366 21.501 29.433 10892.0 0.778
GP5 0.163 0.150 0.178 0.157 0.142 0.174 5214.0 0.218 0.184 0.157 0.209 0.183 0.153 0.214 11700.0 0.894
GP6 5.340 4.262 6.201 6.167 5.056 7.334 4046.0 0.012 6.036 4.952 7.274 6.253 5.229 7.436 11067.0 0.778
GP7 0.365 0.289 0.450 0.402 0.274 0.531 5495.0 0.551 0.452 0.333 0.562 0.442 0.354 0.597 11456.0 0.833
GP8 18.936 17.695 19.801 18.551 17.409 19.584 5297.0 0.428 18.179 16.802 19.415 18.129 17.002 19.232 11641.0 0.833
GP9 9.594 8.789 10.605 9.142 8.198 10.011 4672.0 0.061 9.593 8.564 10.422 9.241 8.488 10.050 10592.0 0.778
GP10 4.910 4.291 5.618 5.172 4.574 6.129 4688.0 0.067 5.083 4.405 5.728 5.134 4.342 6.037 11427.0 0.833
GP11 0.670 0.578 0.732 0.708 0.638 0.821 4489.0 0.061 0.683 0.612 0.756 0.678 0.593 0.765 11853.0 0.987
GP12 0.684 0.544 0.895 0.643 0.466 0.928 5521.0 0.730 0.607 0.456 0.923 0.615 0.477 0.966 11571.0 0.833
GP13 0.264 0.230 0.298 0.258 0.229 0.293 5688.0 0.885 0.261 0.228 0.297 0.257 0.225 0.300 11484.0 0.833
GP14 13.171 11.025 15.405 11.864 9.800 13.913 4284.0 0.051 11.689 8.929 13.593 11.015 8.708 12.681 11005.0 0.778
GP15 1.762 1.595 1.919 1.736 1.482 1.960 5570.0 0.885 1.651 1.445 1.861 1.639 1.438 1.849 11831.0 0.987
GP16 3.126 2.837 3.437 3.086 2.768 3.393 5539.0 0.430 3.086 2.838 3.429 3.071 2.739 3.406 11222.0 0.778
GP17 0.973 0.917 1.088 0.967 0.881 1.110 5638.0 0.885 1.008 0.878 1.125 0.986 0.882 1.119 11677.0 0.833
GP18 9.359 7.857 10.641 8.559 6.916 9.896 4443.0 0.061 7.824 6.701 9.282 7.705 6.738 8.886 11115.0 0.778
GP19 1.992 1.749 2.206 2.010 1.752 2.314 5461.0 0.612 1.966 1.762 2.259 1.952 1.602 2.207 10479.0 0.373
GP20 0.419 0.373 0.471 0.428 0.380 0.472 5837.0 0.885 0.404 0.362 0.460 0.398 0.353 0.455 11154.0 0.778
GP21 0.851 0.783 0.942 0.875 0.792 0.972 5459.0 0.430 0.908 0.834 1.003 0.874 0.802 0.958 9792.0 0.174
GP22 0.165 0.132 0.201 0.173 0.143 0.210 5273.0 0.327 0.148 0.122 0.182 0.146 0.120 0.178 11278.0 0.778
GP23 1.790 1.508 2.226 1.587 1.340 1.888 4307.0 0.025 1.615 1.426 2.035 1.623 1.303 1.847 10358.0 0.373
GP24 1.816 1.637 2.070 1.939 1.669 2.253 5011.0 0.259 1.960 1.735 2.229 1.865 1.559 2.241 10417.0 0.373
Glycoage 0.211 0.053 0.335 0.283 0.155 0.446 4735.0 0.067 0.313 0.207 0.521 0.354 0.245 0.520 11271.0 0.778
Results of the statistics are denoted as Mann Whitney U value (MW U) and adjusted p-value (false discovery rate (FDR) method). GP = glycan peak; GlycoAge index = log 10(FA2/FA2G2);
PTSD: post-traumatic stress disorder.
Biomolecules 2019, 9, 834 8 of 14
6.1. N-glycans in Plasma
Major glycan peak structures are described in Supplementary Tables S1 and S2. To confirm
changes in N-glycan levels in cases/controls, only significantly different N-glycan levels identified
in both the discovery and replication cohorts, and altered in the same direction, were designated as
significant. In the discovery cohort, comprised of 160 PTSD and 73 age-matched control subjects, 19 out
of 39 plasma N-glycans were significantly different between subjects with PTSD and control subjects.
In the replication cohort, comprised of 139 PTSD and 171 age-matched control subjects, only six
plasma N-glycans out of 19 from the discovery study were confirmed to differ significantly between
cases/controls (Table 1). Among these six plasma N-glycans, four (GP14 = A2G2S1, GP27 = A3G3S3,
GP33 = A4G4S3, GP39 = A4F1G4S4) were significantly higher, whereas two (GP16 = FA2G2S1,
GP19 = M9) were significantly lower in PTSD subjects compared to controls in both cohorts (Figure 1).
These results suggested that these six plasma N-glycans might be used as biomarkers of PTSD.
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Figure 1. Distribution of si ificant plasma N-glycans in healthy control subjects and patients
with PTSD, in discovery and replication cohort. GP = glycan peak; GP14 = monosialylated glycan
(A2G2S1); GP16=monosialylated glycan (FA2G2S1); GP19 = high mannose (M9); GP27 = trisialylated
glycan (A3G3S3); GP33 = trisialylated glycan (A4G4S3); GP39 = tetrasialylated glycan (A4F1G4S4);
PTSD = post-traumatic stress disorder.
Biomolecules 2019, 9, 834 9 of 14
6.2. N-glycans Attached to IgG
Only 2 N-glycans bound to IgG (GP6 = FA2B, GP23 = FA2G2S2) differed significantly between
individuals with PTSD and healthy subjects in the discovery cohort, but these findings were not
confirmed in the replication study (Table 2). These results revealed that N-glycans bound to IgG are
not associated with PTSD.
6.3. GlycoAge Test
To evaluate whether N-glycans can be used as indicators of the accelerated aging in subjects with
PTSD [19], a GlycoAge test was calculated for cases/controls in the discovery/replication study (Table 1;
Table 2). There were no significant differences between individuals with PTSD and control subjects
in the GlycoAge values in the discovery study for plasma (p = 0.208) and IgG N-glycans (p = 0.067).
These findings were confirmed in the replication study as both plasma (p = 0.489) and IgG (p = 0.778)
GlycoAge values did not differ significantly between participants with PTSD or control participants.
6.4. N-glycans and PTSD Severity
As plasma N-glycans differed significantly between cases and controls, we assessed the possible
association between plasma N-glycans and PTSD severity using the Spearman’s correlation (Table 3).
Table 3. Correlation between PTSD severity determined by the CAPS scores and distribution of total
plasma N-glycan structures, as well as differences between veterans with moderate and severe PTSD in
discovery and replication cohort.
Plasma N-Glycan Peak
Discovery Cohort (N = 233) Replication Cohort (N = 330)
rho p MW U p rho p MW U p
GP1 0.035 0.791 875.0 0.984 0.076 0.991 612.0 0.921
GP2 0.031 0.801 885.0 0.984 0.009 0.991 644.0 0.921
GP3 0.126 0.364 804.0 0.899 0.078 0.991 562.0 0.921
GP4 0.139 0.330 821.0 0.899 0.003 0.991 615.0 0.921
GP5 0.149 0.330 815.0 0.899 0.034 0.991 576.0 0.921
GP6 0.104 0.388 741.0 0.829 0.076 0.991 683.0 0.969
GP7 0.095 0.395 753.0 0.829 0.119 0.991 687.0 0.969
GP8 0.026 0.826 693.0 0.829 0.009 0.991 649.0 0.921
GP9 0.111 0.388 816.0 0.899 0.037 0.991 668.0 0.969
GP10 0.110 0.388 877.0 0.984 0.017 0.991 635.0 0.921
GP11 0.055 0.735 686.0 0.829 0.060 0.991 699.0 0.969
GP12 0.013 0.904 680.0 0.829 0.020 0.991 648.0 0.921
GP13 0.110 0.388 839.0 0.969 0.020 0.991 508.0 0.921
GP14 0.047 0.773 678.0 0.829 0.005 0.991 570.0 0.921
GP15 0.100 0.388 817.0 0.899 0.014 0.991 525.0 0.921
GP16 0.100 0.388 770.0 0.829 0.012 0.991 544.0 0.921
GP17 0.044 0.784 735.0 0.829 0.018 0.991 641.0 0.921
GP18 0.041 0.791 745.0 0.829 0.001 0.991 685.0 0.969
GP19 0.148 0.330 602.0 0.829 0.204 0.312 593.0 0.921
GP20 0.118 0.388 798.0 0.899 0.004 0.991 605.0 0.921
GP21 0.034 0.791 881.0 0.984 0.092 0.991 625.0 0.921
GP22 0.095 0.395 845.0 0.976 0.029 0.991 605.0 0.921
GP23 0.012 0.904 850.0 0.977 0.097 0.991 514.0 0.921
GP24 0.137 0.330 823.0 0.899 0.025 0.991 696.0 0.969
GP25 0.034 0.791 635.0 0.829 0.205 0.312 505.0 0.921
GP26 0.048 0.773 685.0 0.829 0.070 0.991 586.0 0.921
GP27 0.136 0.330 725.0 0.829 0.064 0.991 452.0 0.921
GP28 0.170 0.330 736.0 0.829 0.012 0.991 676.0 0.969
GP29 0.009 0.914 770.0 0.829 0.058 0.991 672.0 0.969
GP30 0.133 0.330 621.0 0.829 0.018 0.991 693.0 0.969
GP31 0.158 0.330 668.0 0.829 0.117 0.991 641.0 0.921
GP32 0.104 0.388 872.0 0.984 0.008 0.991 602.0 0.921
GP33 0.146 0.330 760.0 0.829 0.011 0.991 508.0 0.921
GP34 0.017 0.901 752.0 0.829 0.134 0.991 590.0 0.921
GP35 0.106 0.388 773.0 0.829 0.038 0.991 515.0 0.921
GP36 0.136 0.330 867.0 0.984 0.093 0.991 580.0 0.921
GP37 0.056 0.735 696.0 0.829 0.002 0.991 614.0 0.921
GP38 0.074 0.575 772.0 0.829 0.028 0.991 695.0 0.969
GP39 0.151 0.330 806.0 0.899 0.025 0.991 628.0 0.921
GlycoAge 0.036 0.791 875.0 0.984 0.013 0.991 689.0 0.969
Results of the statistics are denoted as Spearman’s rho coefficient (ρ), Mann Whitney U value (MW U), and
corresponding adjusted p value (false discovery rate (FDR) method). GP = glycan peak; GlycoAge index = log10
(FA2/FA2G2); PTSD = post-traumatic stress disorder.
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In our sample, most of the patients with PTSD had moderate symptoms (92% in both cohorts),
whereas the remainder were diagnosed with severe PTSD. No significant correlations were detected
between any of the plasma N-glycans and severity of PTSD in discovery or replication cohort (Table 3).
Additionally, differences in plasma N-glycans between patients with moderate and severe PTSD,
evaluated with Mann–Whitney U test, were not significant. These results confirmed the lack of
association between plasma glycosylation and severity of PTSD symptoms (Table 3).
Furthermore, individuals with moderate and severe PTSD had similar GlycoAge values in the
discovery (p = 0.984) and replication cohort (p = 0.969) (Table 3). These results revealed that PTSD
severity was not associated with GlycoAge index in individuals with PTSD.
7. Discussion
7.1. N-glycans in Plasma
This is the first study to show significant associations of the plasma, but not IgG, N-glycans with
combat-related PTSD. These results, confirmed in both discovery and replication study, have shown
in a fairly large sample size, that four plasma N-glycans (A2G2S1, A3G3S3, A4G4S4, A4F1G4S4)
were increased, whereas two plasma glycan species (FA2G2S1, M9) were decreased in individuals
with PTSD compared to control subjects. Furthermore, individuals with PTSD did not show signs of
accelerated physiological aging compared to healthy control subjects, determined with GlycoAge Test
index [14,19]. Additionally, severity of PTSD was not associated with plasma N-glycans.
Although several studies have analyzed N-glycosylation profiles in psychiatric and
neurodegenerative diseases [31]; Moreno-Villanueva’s study [19] was the only one that analyzed
these changes in PTSD subjects. Their study [19] focused on nine N-glycan structures in plasma
of 32 individuals: 13 medicated subjects with PTSD, comorbid with MDD, nine trauma-exposed
individuals and 10 low-stress control subjects of different ethnicities. In contrast to our results, they
found no significant differences in plasma N-glycans between these groups [19]. However, our study
analyzed N-glycosylation profile (39 N-glycan species in plasma and 24 attached to IgG) on a much
larger and homogenous sample (N = 543) of medication-free males (PTSD/controls), without MDD or
other comorbidities.
As N-glycosylation is associated with accelerated aging, a GlycoAge Test has been proposed to
predict physiological aging in healthy populations [14]. Higher GlycoAge values have been reported in
individuals with AD [14] and PTSD [19], when compared to healthy controls matched for age. Although
there was a significant association of GlycoAge values with chronological age in both PTSD and control
subjects in our study, there were no significant differences in its values between PTSD/controls, after
correcting for age and multiple testing in the large sample of male Caucasian veterans with PTSD.
Further modeling of GlycoAge test formula with other identified N-glycan species, obtained in our
study, due to more precise separation, and possibly inclusion of additional biochemical and metabolic
parameters [32], could yield more accurate results.
Plasma N-glycan profile in PTSD patients from both cohorts was characterized by a greater
abundance of highly branched (tri-antennary and tetra-antennary) structures, that were more
galactosylated and sialylated (A3G3S3, A4G4S4, and A4F1G4S4). This pattern is identified in acute
and chronic inflammation states [33], and in patients 24–48 h after abdominal surgery [34]. Increased
highly sialyated and glycosylated N-glycan species (A3F1G3S3 and A4G4LacS4 in low abundant
proteins, and A3F1G3S3, A4G4S2, A4G4S3, FA3G3S3, and FA3BG3S3 in highly abundant proteins)
were detected in sera of male schizophrenic subjects [15]. Patients with PTSD often exhibit psychotic
symptoms [35] that are hallmarks of schizophrenia. Therefore, a similar N-glycosylation profile in
these two disorders is not unexpected. A3F1G3S3 N-glycan containing a sLex epitope, that is associated
with increased immunological reaction to antigens [36] and metastasis [37], was significantly increased
in both low and high abundant proteins [15]. In our study, A4F1G4S4 N-glycan, that also contains
sLex epitope, was significantly increased in both cohorts, similarly to results in the recently operated
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patients [34]. Increased glycan branching in total plasma proteins, detected in our veterans with PTSD
has previously been found to positively correlate with severity of MDD [16], a common comorbidity
in patients with PTSD. Although our veterans did not have clinical MDD, they share some common
depressive/numbing symptoms and similar N-glycan changes. In contrast to the results of present
study, increased peripheral fucosylation of biantennary glycans and decreased branching, including
tri- and tetraantennary glycans, was detected in ADHD in our previous study [17]. These differences
might be explained with different diagnoses (ADHD vs. PTSD), differences in gender and age (average
9-year-old male and female children with ADHD vs. 54-year-old male veterans with PTSD and control
male participants).
In our study, high-mannose (M9) and core-fucosylated (FA2G2S1) plasma glycan species were
significantly decreased in the PTSD group, compared to the low-stress healthy control, and this result
corresponds to lower glycan species found in inflammation [34]. As alternations of high-mannose
glycans have been associated with occurrence and progression of different types of cancers [38–40],
neuropsychiatric disorders [41], inflammation [34] and brain aging [42], whereas PTSD is associated
with inflammation [17] and cardiometabolic disorders [4,5], the lower FA2G2S1 glycan result suggests
that veterans with PTSD should be closely monitored for these disorders.
Traumatic load was reported to be positively correlated with the GlycoAge Test in subjects with
substantial trauma exposure [19]. In our study, severity of PTSD was not significantly associated with
plasma N-glycans. This could be explained by the fact that our study included PTSD patients with
similar trauma experience and duration, and the fact that 92% of our patients had moderate symptoms
of PTSD in both cohorts.
7.2. N-glycans Attached to IgG
We found two IgG glycoforms to be significantly different between PTSD and control subjects in
the first cohort. Core fucosylated bisecting agalactosylated N-glycan FA2B was significantly increased
in patients with PTSD, while more sialyated and galactosylated form, FA2G2S2, was significantly lower.
Core fucosylated N-glycans on IgG are generally considered anti-inflammatory as core fucosylation of
IgG can drastically increase antibody-dependent cytotoxicity [43], while decreased galactosylation
containing bisecting GlcNAC on IgG is usually hallmark of inflammation and older age [32]. However,
the replication cohort did not confirm these changes in FA2B and FA2G2S2 after correcting for multiple
testing. Previous research in IgG N-glycome of patients with MDD (male and female combined) has
found only two significant glycoforms, both containing bisecting GlcNAC, but similar to our results,
there were no significant correlations when males were analyzed separately [16].
8. Conclusions
We selected two large and balanced cohorts in order to identify potential alterations in
N-glycosylation pattern characteristic for PTSD. Strength of the study is in a relatively homogeneous
sample of age- and sex-matched PTSD patients and controls, with strict exclusion criteria. To ensure
that our findings are due to a true biological variation, and to eliminate any possible experimental
artefacts and false positive findings due to chance, we replicated our results using a second cohort.
Besides, the study analyzed both plasma and IgG N-glycosylation with high-resolution separation
techniques and reported only the results that were significant in both discovery and replication cohort,
after adjustment for age and multiple testing. To avoid possible bias, plasma samples in both cohorts
were randomized and blinded prior to N-glycan determination. However, we still detected differences
between discovery and replication cohort that we cannot yet explain, possibly due to other biological
parameters or unknown confounders that we did not take into account during sampling and/or
statistical analysis.
Limitation of this study is in a relatively narrow subpopulation of patients of the same ethnicity,
gender and type of trauma. To validate obtained results, inclusion of women, different ethnicities,
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individuals exposed to different types of trauma, as well as trauma-exposed controls without PTSD
is necessary.
In conclusion, this is the first study detecting alterations in the selected plasma N-glycans in
PTSD. Our results suggest that PTSD share similar biological underpinning as other neuropsychiatric
disorders and inflammation and could point out to some common glycosylation mechanisms underlying
neuropsychiatric disorders and inflammation.
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